An observational study in Conductive Hearing Loss, Mixed Hearing Loss and Sensorineural Hearing Loss, sponsored by MED-EL Elektromedizinische Geräte GmbH. Enrolling by invitation at 1 site in Germany. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by MED-EL Elektromedizinische Geräte GmbH · Observational
This observational registry collects retrospective and prospective, data from children and adults who use CE-marked MED-EL implantable (PMEI, BCI, or AMEI) or non-implantable (BCD) hearing solutions as part of routine care. Participants will be followed long term, potentially up to the lifetime of their hearing solution, to assess quality of life, hearing and speech performance, and device use. Data will be collected using routinely administered clinical tests and questionnaires to evaluate real-world outcomes across diverse populations and MED-EL hearing systems.
82 studies on the registry are indexed under Hearing Loss, Conductive; 15 are open to participants now.
This study's planned enrollment of 50 is below the median of 71 across 20 observational studies indexed under Hearing Loss, Conductive.
Browse Hearing Loss, Conductive studies →MED-EL Elektromedizinische Geräte GmbH is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants of any age who are treated in routine clinical care with a CE-marked MED-EL implantable or non-implantable hearing solution, used according to its intended purpose, may be included. No additional burdensome or invasive procedures beyond standard clinical care and normal device use are required.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VSB
BB
Adhear
PMEI
Patient reported hearing benefit
Patient reported speech, spatial and qualities of hearing and auditory performance will be assessed by the Speech, Spatial, and Qualities of Hearing questionnaire (SSQ-12 or SSQ P).
Time frame: Data may be analysed at predefined follow-up intervals corresponding to the following time periods after treatment: 0 to 3 months, >3 to 12 months, >12 to 24 months, >24 to 60 months, and beyond 60 months.
Patient reported health status
Patient reported health status will be assessed by the Glasgow Benefit Inventory (GBI or GCBI).
Time frame: Data may be analysed at predefined follow-up intervals corresponding to the following time periods after treatment: 0 to 3 months, >3 to 12 months, >12 to 24 months, >24 to 60 months, and beyond 60 months.
Hearing improvement
Hearing improvement will be assessed by sound field thresholds (SF).
Time frame: Data may be analysed at predefined follow-up intervals corresponding to the following time periods after treatment: 0 to 3 months, >3 to 12 months, >12 to 24 months, >24 to 60 months, and beyond 60 months.
Speech intelligibility
Speech intelligibility will be assessed by the word recognition score (WRS). The Word Recognition Score percentage scale ranges from a minimum value of 0%, which means no words were understood, to a maximum value of 100%, which means all words were understood.
Time frame: Data may be analysed at predefined follow-up intervals corresponding to the following time periods after treatment: 0 to 3 months, >3 to 12 months, >12 to 24 months, >24 to 60 months, and beyond 60 months.
Speech intelligibility
Speech intelligibility will be assessed by the speech reception threshold in quiet (SRT) and in noise (SNR)
Time frame: Data may be analysed at predefined follow-up intervals corresponding to the following time periods after treatment: 0 to 3 months, >3 to 12 months, >12 to 24 months, >24 to 60 months, and beyond 60 months.
Preservation of hearing thresholds
Preservation of hearing thresholds will be assessed by air conduction thresholds (AC) and /or bone conduction (BC) thresholds.
Time frame: Data may be analysed at predefined follow-up intervals corresponding to the following time periods after treatment: 0 to 3 months, >3 to 12 months, >12 to 24 months, >24 to 60 months, and beyond 60 months.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jul 2036, 116 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MED-EL Elektromedizinische Geräte GmbH